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Background: Parenteral artesunate is recommended as first-line therapy for severe and complicated malaria. Although
its efficacy has been proven, long-term safety profile is still under evaluation. Several cases of delayed haemolytic
anaemia occurred after initial clinical improvement and resolution of parasitaemia in non-immune travellers and
children living in endemic areas. Reports have generated concern that this phenomenon might be related to
the treatment itself, either by direct toxicity or immune-related mechanism. This is a report of the first case of
autoimmune haemolytic anaemia following treatment of severe malaria initially managed with parenteral
artesunate with strong indication for drug-immune related mechanism.
Case: A 17-year old Ivoirian female travelling in France presented with fever, headache and abdominal pain seven
days after her arrival. Physical examination was indicative of septic shock while blood analysis showed normal
haemoglobin level, but profound thrombocytopaenia and hyperlactataemia. Blood smear analysis showed
Plasmodium falciparum infection with a parasitaemia of 0.8%. Severe malaria was diagnosed according to the
WHO criteria. The patient was initially managed with artemether/lumefantrine combination and then parenteral
artesunate for 48 hours. Empiric antibiotic course was also initiated with ceftriaxone, metronidazole, gentamycin,
and then piperacillin and ciprofloxacin. At day 14, haemoglobin dropped to 4.6 g/dL with biologic features
indicative of haemolysis (LDH 658 U/L, haptoglobin <0.15 g/L). At that time, parasitaemia was negative and other
infections or hereditary disorders were excluded, while Coombs’ direct antiglobulin test was positive for IgG and
C3d. Antinuclear antibodies were absent. Further investigations evidenced drug-induced antibodies related to
artesunate. It was concluded a drug-mediated autoimmune haemolytic anaemia. A corticosteroids regimen was
initiated at 1 mg/kg/day. Outcome was favourable and corticosteroids were progressively tapered during two
months. At present the patient’s condition remains stable without recurrence of haemolytic anaemia.
Conclusion: This is the first case of delayed haemolytic anaemia related to artesunate with a strong indication for
drug-immune related mechanism. Further research is warranted to better characterize this plausible cause of
post-treatment haemolysis following parenteral artesunate administration in severe malaria patients.
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Infection with Plasmodium falciparum malaria remains
a major risk for northern countries’ travellers returning
from malaria-endemic areas. According to WHO guide-
lines and recommendations of the European Society for
Clinical Microbiology and Infectious Diseases, intravenous
(iv) artesunate should be considered as first-line treatment
for severe malaria, instead of quinine [1]. While superiority
in terms of survival has been proven when iv artesunate
was compared to quinine in controlled trials in Asia
(SEAQUAMAT) [2] and Africa (AQUAMAT) [3], little
evidence is available regarding long-term side effects.
Recently, several reports pointed out occurrence of
late-onset haemolysis secondary to artesunate adminis-
tration [4-8]. Most of the cases did not show a clear
mechanism underlying this phenomenon, in particular
auto-immune mediated processes. Here is reported the
first case of auto-immune haemolytic anaemia (AIHA)
following treatment of severe malaria initially managed
with parenteral artesunate with strong indication for
drug-immune related mechanism.
Case report
A 17-year old Ivorian female without remarkable med-
ical history was admitted for fever, chills, headache, and
abdominal pain in a French University Hospital Centre
(day 1). She had left Ivory Coast seven days earlier to
live in France for studying purpose and symptoms began
two days before her admission. Initial physical examination
showed a temperature of 39°C and pain when palpating
right hypocondrium. Blood tests demonstrated a normal
leucocyte count, a thrombocyte count of 11,000/mm3
(normal range 150,000-450,000), a haemoglobin level of
12.6 g/dL (12–16) with abnormalities indicative of
haemolysis: rise in lactate dehydrogenase (LDH) at 500
U/L (5–248) and total bilirubin at 105 μmol/L (3–18)
with a low haptoglobin of 0.15 g/L (0.3-2). She was di-
agnosed with uncomplicated malaria as peripheral thin
blood film showed P. falciparum trophozoites (0.8% of
parasitized erythrocytes). Abdominal ultrasonography
ruled out biliary tract or gall bladder infection. A treat-
ment with oral artemether/lumefantrine combination
(Riamet©) was initiated with respectively, 80 and 480 mg
trice within the first 24 hours of hospitalization (total of
240 mg of artemether and 1440 mg of lumefantrine). On
day 2, her clinical condition deteriorated, her blood pres-
sure dropped to 80/40 mmHg together with a pulse rate of
130 bpm. Laboratory tests indicated a fall of thrombocyte
count at 6,000/mm3 and elevation of blood lactate up to
7.4 mmol/L (N < 2). The patient was now classified as
complicated malaria and admitted to intensive care unit.
Treatment was switched to intravenous artesunate
(Malacef®, ACE Pharmaceuticals, The Netherlands), started
at three doses of 120 mg (2.4 mg/kg body weight) with 12-hour interval. Concurrently she was managed with sup-
portive care, that was administration of 2 l normal saline
solution and two units of packed thrombocytes. The use of
norepinephrine up to 0.5 μg/kg/min was required during
24 hours to restore a normal blood pressure. The septic
shock condition was managed by a course of empiric anti-
biotic treatment, i.e., ceftriaxone 2 g/day, gentamycin
3 mg/kg/day and metronidazole 1.5 g/day. Evolution was
marked by rapid improvement as blood pressure main-
tained at normal values, and fever disappeared. Lactate
level returned within normal range and parasitaemia
declined under 0.1% of red blood cells (RBCs). Twelve
hours after the last dose of artesunate (total of three doses,
360 mg), the patient was transferred to a regular ward of
tropical medicine (day 4). Anti-malarial treatment was
continued orally with two daily doses of 80 mg artemether
and 480 mg lumefantrine until day 6 (total of 480 mg of
artemether and 2880 mg of lumefantrine). Antibiotics were
changed to piperacillin/tazobactam (12 g daily) and cipro-
floxacin 500 mgx2/day. Despite initial favourable evolution
and total clearance of parasites, fever reappeared on day 8.
Of note, a drop in haemoglobin up to 6.3 g/dL was evi-
denced while thrombocytosis was associated: 489 G/L.
The Coombs’ test performed at that time was negative.
The patient left hospital against medical advice but was
re-admitted on day 14 because of persistent fever and
marked asthaenia.
Blood analysis confirmed anaemia with a decrease in
haemoglobin at 4.6 g/dL and the subsequent criteria for
haemolysis: reticulocyte count of 202,000/mm3, LDH
flare up to 658 U/L and undetectable haptoglobin level.
Repeated blood films for malaria as well as for schisto-
cytes (i.e. fragments of RBCs produced by extrinsic
mechanical damage within the circulation) were negative.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
was promptly ruled out and haemoglobin electrophoresis
did not reveal any abnormality. On the other hand, direct
Coombs’ test revealed positivity for both IgG and comple-
ment factor C3d while this test was negative five days earl-
ier. The irregular antibody testing was negative. It was
concluded AIHA and complementary aetiological inquiry
was performed. Antinuclear antibodies were absent and
the investigation was negative for numerous pathogens
such as bacteria (Mycoplasma pneumoniae, Chlamydia
pneumoniae, Salmonella typhi and Salmonella paratyphi),
viruses (dengue virus, CMV, EBV, parvovirus B19, HBV,
HCV, and HIV) or parasites (Leishmania spp, Entamoeba
histolytica).
In the context of unusual immunohaematological
haemolysis, no transfusion was attempted and cortico-
steroids were introduced. Methylprednisolone pulses of
60 mg per day during seven days were performed. The
haemoglobin level gradually improved (Figure 1). On dis-
charge (day 24), haemoglobin was 8.8 g/dL and treatment
Figure 1 Evolution of an auto-immune haemolytic anaemia developed during severe malaria treated with intravenous artesunate and
other antimicrobial chemotherapy. Ar = artemether; As = artesunate; CFTX = ceftriaxone; CPFX = ciprofloxacin; DAT = direct antiglobulin test;
LDH = lactate dehydrogenase; Lu = lumefantrine; PTZ = piperacillin and tazobactam
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The corticosteroids dosage was progressively tapered
during the two following months before discontinuation.
Haemoglobin level slowly increased and from day 52 it was
measured above the 12 g/dl threshold. At that time hapto-
globin and LDH were within normal limits. Consistently,
direct Coombs’ test was negative, both for IgG and C3d.
During the follow-up, the patient completely recovered
and her condition remained stable 12 months later.
Concurrently, she was additionally tested for drug-
dependent antibodies by ex vivo antigen testing. Serum
samples were screened during the convalescent phase, i.e.
12 months, as no biological sample of the acute phase
could be retrieved. The test used the main suspected
medication substrates, namely ceftriaxone, and three dif-
ferent pharmaceutics specialties containing derivative of
artemisin: Riamet®, artemether alone and Malacef (artesu-
nate). This testing was conducted according to a home-
made method developed by the French Blood Institute
according to standardized reports [9-11] and detailed in
the method section.
Among all tested drugs, the test was positive only
with artesunate in the papain-pretreatment condition
(Table 1). Thus, no other drug could induce haemoly-
sis, even with papain-treated RBCs. This positivity was
obtained using two distinct procedures, applied with
the three required concentrations of artesunate. This
was indicative of the persistence of drug antibodies
related to artesunate, even one year after the episode of
haemolytic anaemia.Methods
The patient’s samples (15 mL of ethylene diamine tetra-
acetate blood and 15 mL of serum) were referred to the
French Blood Institute of Bordeaux. Sera of healthy indi-
viduals of AB blood group that willingly give their blood
to the French Blood Institute served as negative controls
and were referred as healthy donors. The initial antibody
identification was performed using an IAT (anti-IgG and
anti-C3d) tube method, with native and papain-treated
RBCs (French National Reference Center for Blood Group
typing -CNRGS, France). Papain is an enzyme that potenti-
ates the agglutination reaction by reducing the negative
charges on the surface of RBCs, thus allowing greater ac-
cessibility of some epitopes. Papain treatment of the tested
RBCs was performed according to the manufacturer’s rec-
ommendations (Papain Palerm, Diagast, Loos, France): one
volume of papain solution was added to one volume of
washed RBCs. After an incubation of 15 min at 37°C,
RBCs were washed three times. Serum samples of the
patient were incubated during one hour at 37°C with a
panel of erythrocyte and various concentrations of the
drugs mentioned above: pure, diluted to 1/10, and esti-
mated therapeutic concentration. Then, agglutination of
RBCs was tested with indirect antiglobulin test using anti-
IgG or anti-C3d as well as papain pretreated erythrocytes.
As negative controls, saline solution and the complement
source (pooled, fresh serum of healthy donors of AB blood
group) were both tested with and without the drug
solution added to reagent RBCs. The positive control re-
ferred to erythrocytes incubated with a serum-containing
Table 1 Testing for drug-dependent antibodies during convalescent period
Patient serum samples Healthy donor sera Positive control
As Ar Ar/Lu CFTX saline As saline anti-Fya antibody
IAT IgG 0 0 0 0 0 0 0 ++
IAT C3d 0 0 0 0 0 0 0
Papain pretreatment + 0 0 0 0 0 0
Ar = artemether; As = artesunate; CFTX = ceftriaxone; IAT = indirect antiglobulin test; Lu = lumefantrine.
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namely Fya. The result of the test was estimated by the de-
gree of RBCs agglutination with a macroscopic evaluation.
If RBCs were not sensitized by antibodies, they were not
stuck together and were found at the bottom of the tube
(reaction scored ‘0’). If RBCs were sensitized by antibodies,
they would remain clustered at the surface column and
this reaction was graded from 1 to 4+, 4+ being the stron-
gest positive reaction.
Discussion
To date, up to 19 cases of putative artesunate-related,
late-onset haemolysis have been described in the litera-
ture among patients with severe malaria who returned
from malaria-endemic regions [4-8]. All patients were
non-immune hyperparasitaemic (>5%) travellers from
northern countries and haemolysis occurred one to four
weeks after parenteral use of artesunate. All patients recov-
ered completely although haemolysis decreased slowly.
Concurrently, delayed haemolysis has been recently re-
ported in five among 72 hyperparasitaemic African chil-
dren, recruited in Gabon or Ghana, and treated with
parenteral artesunate for severe malaria [12]. Thus a total
of 24 cases of unusual haemolytic anaemia following intra-
venous artesunate administration have been reported so
far. The aetiology of this complication is still unknown.
The fact that mainly hyperparasitaemic patients devel-
oped this condition has been related by some to a mech-
anism called ‘pitting’. After extraction of blood stage
parasites during splenic passage, these once-infected
erythrocytes have a reduced lifespan compared to naïve
erythrocytes with a mean lifespan of around 180 hours
and with a total removal of pitted erythrocytes after 28
days. A hypothesis is that haemolytic activity may
increase two weeks after acute malaria due to synchro-
nized destruction of pitted erythrocytes [13,14]. Of note,
the patient described here did not show hyperparasitae-
mia at any time of her history. Besides she originated
from West Africa and her presumed semi-immune pro-
file might refer to the initial parasitaemia characterized
by a low load level.
Haemolytic anaemia is a challenging situation for physi-
cians as multiple causes may be involved [15,16]. The char-
acteristic laboratory features are reticulocytosis, increase of
unconjugated bilirubin and lactate dehydrogenase, as wellas decreased haptoglobin levels. The patient described here
presented with these typical abnormalities at first and sec-
ond admittance. If it is a certainty that malaria was respon-
sible of haemolytic anaemia during the first week, the
negative finding for blood smear ruled out its implication
in the re-appearance of haemolysis. When there is no obvi-
ous aetiology for that kind of anaemia, it is classical to
distinguish hereditary (corpuscular) and acquired causes of
haemolysis. The former comprises haemoglobinopathies
(such as thalassaemia and sickle cell disease), membrano-
pathies (e.g., hereditary spherocytosis) and enzymopathies,
such as G6PD deficiency. Blood smear is mandatory to
assess some of these causes, and must be completed if
necessary by electrophoresis of haemoglobin and/or
measurement of G6PD activity. Here, all these tests
were negative and the inquiry focused on the process
surrounding this acquired haemolytic anaemia: infection,
microangiopathy or immune-mediated process. Concern-
ing infectious diseases, relapsing malaria and babesiosis
were ruled out, while the lack of schistocytes and thrombo-
cytopaenia argued against microangiopathy. Finally, an
immune mechanism was evoked and assessed by a positive
direct antiglobulin (Coomb’s) test which is highly sensitive
and relatively specific [17,18]. As the diagnosis of immune-
mediated anaemia was confirmed, it had to be classified as
auto-immune, allo-immune or drug-induced. Allo-immune
haemolytic anaemia could easily be excluded because the
patient did not receive RBC transfusion and irregular anti-
body testing was negative. Concerning AIHA, researches
did not show an underlying condition (secondary AIHA)
such as a connective tissue disease, a lymphoproliferative
disorder or an infection, especially Mycoplasma pneumo-
niae or Epstein Barr Virus-related-mononucleosis. It seems
that malaria itself has never been described as a potential
cause of AIHA. Although most cases of AIHA are idio-
pathic, the context of multiple drugs intake and recovery
within a few weeks were in favour of a drug-induced
immune haemolytic anaemia (DIIHA). Indeed, when a
drug responsible for DIIHA is discontinued, the haemolytic
anaemia resolves soon afterwards, while during idiopathic
AIHA evolution is often chronic or recurrent. In the
present case, all suspected treatments were stopped ap-
proximately at the same time, what does not permit to
charge one in particular. Of note, the patient did not re-
ceive artemisin-derivative for previous malaria fever.
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ism responsible of artesunate-related delayed haemolytic
anaemia. In the cases of DIIHA, the direct Coombs’ test
(DAT) is usually positive, thus being a prerequisite for
hypothesize DIIHA [10]. Thus, among reported cases of
artesunate-related delayed haemolytic anaemia, four indi-
cated positivity of Coombs’ test among 12 patients tested
[4-6] (Additional file 1). One of these cases showed positiv-
ity of indirect antiglobulin test (IAT) consecutive to allo-
immunization following previous transfusion [6]. More-
over, IAT was negative in three patients who experienced
late-onset haemolysis following artesunate therapy, includ-
ing one patient with documented negative Coombs’ test
[4]. To date, the case reported here is the first describing
delayed occurrence of auto-immune anaemia in severe
malaria treated with parenteral artesunate with strong
indication for drug immune-related contribution.
DIIHA is a rare condition, as the estimated incidence
is of one per million population per year. Three mecha-
nisms are described: drug absorption (hapten-induced),
immune complex formation with the drug on RBC sur-
face or auto-antibody production resulting in IgG and/or
IgM (C3d complement) positivity in direct antiglobulin
test [10]. Numerous medications can induce production
of antibodies against RBCs, thus positive DAT and IAT,
and most of these conditions are clinically and serologic-
ally indistinct from AIHA [10,19]. The commonest drugs
involved are anti-infective treatments, especially penicillin
and cephalosporins, non-steroidal anti-inflammatory and
anti-neoplastics. Given that in the reported case, the pa-
tient received several drugs during the week before positive
diagnosis of AIHA, it is difficult to assess which one is
responsible. Ceftriaxone has been frequently recognized
as a cause for DIIHA [20-22], mainly in children who
had previously received the antibiotic, unlike in this case.
Piperacillin- and ciprofloxacin-induced IHA have seldom
been described [10,19] and, owing to its rarity, these drugs
were not screened during IAT of convalescent phase.
Concerning lumefantrine, some cases of haemolytic
anaemia are reported [23]. However, most of them can be
considered blackwater fever, a syndrome consecutive to
anti-malarials of amino-alcohol group and characterized
by severe intravascular haemolysis, haemoglobinuria, acute
renal failure, occurring immediately after treatment beyond
an immuno-allergic pattern. On the other hand, only one
case of IHA with lumefantrine was retrieved [24]. In the
present case, the patient did not present the clinical and
serological findings classically described for DIIHA sec-
ondary to ceftriaxone, piperacillin or lumefantrine. Thus it
can be hypothesized that the immune-mediated haemo-
lytic anaemia experienced by the patient could be attribut-
able to the use of artesunate. One year after recovering,
tests were conducted for screening in vitro induction of
haemolysis with several of the employed drugs. Usuallythese tests can show immune-mediated haemolysis
dependent of the presence of the medication, indicative of
drug-dependent antibodies, but they are not performed
routinely by most of the laboratories. The results of these
tests were indicative of an artesunate-mediated auto-
immune haemolysis. Of note, the positive result was evi-
denced using papain pretreated RBCs, which is considered
to enhance the sensitivity for detection of antibody re-
sponse challenges, as described elsewhere [25]. Such re-
sults were not evidenced with the other derivatives of
artemisin-based regimens administered to the patient. Of
note, even if papain is aimed to increase sensitivity, the re-
sult from our analysis definitely argues for the involvement
of artesunate.
Whether this suspected immune-mediated haemolysis is
a consequence of artesunate itself or of its excipients is
questionable. Indeed, no case of artesunate-associated
haemolysis were reported in USA, where the medication is
produced by the Army Medical Material Development Ac-
tivity, while in other countries the manufacturing process
is different [26].
Finally, outcome was slowly favourable while using
glucocorticoids, although this may be coincidental. Man-
agement of DIIHA requires discontinuing the suspected
medication: it is often the only treatment. Actually, effi-
cacy of steroids is uncertain because data are limited to
case reports and the discontinuation of the drug at the
same time is a confounding factor.
Conclusion
Delayed haemolysis is a frequent and relevant complication
in patients treated with parenteral artesunate for severe
malaria. The aetiology of this phenomenon is still unknown
but the drug may act as substrate for autoimmune mechan-
ism. Patients undergoing this drug should be closely moni-
tored with prolonged follow-up including, in patients with
delayed haemolysis, a specific immunological investigation.
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